Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VBIV

VBIV - VBI Vaccines Inc Stock Price, Fair Value and News

$0.020.00 (0.00%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

VBIV Price Action

Last 30 days

-71.4%

Last 90 days

-96.7%

Trailing 12 Months

-98.4%

VBIV RSI Chart

VBIV Valuation

Market Cap

573.6K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.06

EV/EBITDA

-0.48

Price/Free Cashflow

-0.01

VBIV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VBIV Fundamentals

VBIV Revenue

Revenue (TTM)

9.4M

Rev. Growth (Yr)

150.31%

Rev. Growth (Qtr)

42.32%

VBIV Earnings

Earnings (TTM)

-83.0M

Earnings Growth (Yr)

35.5%

Earnings Growth (Qtr)

-137.6K%

VBIV Profitability

Operating Margin

2.58%

EBT Margin

-881.79%

Return on Equity

-1.1K%

Return on Assets

-110%

Free Cashflow Yield

-9.0K%

VBIV Investor Care

Shares Dilution (1Y)

233.18%

Diluted EPS (TTM)

-4.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.4M000
20231.4M1.8M8.1M8.7M
2022456.0K660.0K870.0K1.1M
2021947.0K905.0K714.0K631.0K
20202.3M1.8M1.5M1.1M
20193.1M2.8M2.5M2.2M
2018916.0K806.0K872.0K2.1M
2017627.0K889.0K801.0K865.0K
2016853.3K751.5K649.8K548.0K
2015000955.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About VBI Vaccines Inc

VBIV
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
 CEO
 WEBSITEvbivaccines.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES190

VBI Vaccines Inc Frequently Asked Questions

What is the ticker symbol for VBI Vaccines Inc? What does VBIV stand for in stocks?

VBIV is the stock ticker symbol of VBI Vaccines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VBI Vaccines Inc (VBIV)?

As of Fri Sep 06 2024, market cap of VBI Vaccines Inc is 573.65 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VBIV stock?

You can check VBIV's fair value in chart for subscribers.

Is VBI Vaccines Inc a good stock to buy?

The fair value guage provides a quick view whether VBIV is over valued or under valued. Whether VBI Vaccines Inc is cheap or expensive depends on the assumptions which impact VBI Vaccines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VBIV.

What is VBI Vaccines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Sep 06 2024, VBIV's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VBIV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on VBI Vaccines Inc's stock?

In the past 10 years, VBI Vaccines Inc has provided -0.613 (multiply by 100 for percentage) rate of return.